Comparative Pharmacology
Head-to-head clinical analysis: ESTROSTEP FE versus NORINYL 1 35 21 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTROSTEP FE versus NORINYL 1 35 21 DAY.
ESTROSTEP FE vs NORINYL 1+35 21-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone acetate produces progestational effects including endometrial transformation and cervical mucus thickening, inhibiting sperm penetration and implantation.
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary-ovarian axis, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial structure to impair sperm penetration and implantation.
One tablet daily orally, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (24 active tablets) followed by ferrous fumarate 75 mg tablets (4 placebo tablets).
One tablet orally once daily for 21 consecutive days, followed by 7 days off therapy.
None Documented
None Documented
Ethinyl estradiol: 13-27 hours (terminal); norethindrone acetate: 5-14 hours. Clinical context: Steady-state reached within 7-10 days.
Norethindrone: 7-8 hours; Ethinyl estradiol: 13-27 hours (mean ~17 hours). Steady state achieved by day 10-14.
Renal: ~40% as metabolites; fecal: ~30% (biliary); remainder as conjugates.
Renal (50-60% as metabolites, primarily glucuronide and sulfate conjugates) and fecal (30-40% as metabolites). Less than 1% excreted unchanged.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive